TIDMIXI

RNS Number : 5401M

IXICO plc

12 May 2020

IXICO plc

("IXICO" or the "Company")

Notice of Results

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces it will release its interim results for the six months ended 31 March 2020 on Wednesday 20 May 2020.

A recording of the results presentation will be made available on the Company's website on the morning here: https://ixico.com/investors/company-information/investor-videos/

For further information please contact:

 
 IXICO plc                                                           +44 (0)20 3763 7498 
 Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer 
 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                                                   +44 (0)20 7397 8900 
 Giles Balleny / Max Gould (Corporate 
  Finance) 
 Michael F Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                              Tel: 020 7933 8780 or IXICO@walbrookpr.com 
 Paul McManus / Lianne Cawthorne /                        Mob: 07980 541 893 / 07584 391 
  Alice Woodings                                                                   303 / 
                                                                           07407 804 654 
 
 
 

About IXICO

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.

Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

More information is available on www.IXICO.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORBUGDURDBDGGB

(END) Dow Jones Newswires

May 12, 2020 02:00 ET (06:00 GMT)